Warburg Pincus enters exclusive negotiations to acquire a significant minority stake in Sebia
Existing shareholders CVC Funds, La Caisse (formerly CDPQ) and Téthys Invest to remain significant investors
Lisses, Amsterdam and London, 16 October 2025 – Sebia, a global leader in specialty diagnostics, and Warburg Pincus, the pioneer of private equity global growth investing, today announced that Warburg Pincus has entered into exclusive negotiations for the potential acquisition of a significant minority stake in Sebia.
Sebia is a global specialized In Vitro Diagnostics player providing equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, Autoimmune and Infectious diseases and other rare pathologies. The company serves customers in more than 140 countries through a broad installed base and a portfolio of proprietary reagents and instruments.
Jean-Marc Chermette,Chief Executive Officer of Sebia, said: “Our mission is to provide powerful tools that translate what is happening in a patient’s body into a readable and interpretable language. We welcome Warburg Pincus as a new partner alongside our existing investor base. Their global healthcare expertise and growth orientation will help accelerate Sebia’s strategy while maintaining our commitment to scientific rigor, product quality and patient impact, helping us deliver for our customers and partners.”
TJ Carella, Managing Director and Global Head of Healthcare, and Jake Strauss, Managing Director and Head of European Healthcare at Warburg Pincus, said: “Sebia is a best-in-class diagnostics platform with differentiated technology and a strong track record of delivering innovative products and solutions to customers and patients worldwide. We are excited to partner with Jean-Marc, the management team, and existing shareholders to support the company’s next phase of growth, including continued advances in diagnostic modalities, scientific excellence and manufacturing capabilities.”
The terms of the proposed transaction are not disclosed. Following completion, Sebia will continue to operate as an independent company from its headquarters in Lisses, France.
Execution of the proposed transaction remains subject to completion of applicable employee consultation processes, and receipt of customary regulatory approvals. Closing is expected to occur no earlier than Q1 2026.
About Sebia
Founded in 1967, Sebia is a world-leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in vitro diagnostic testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma) and metabolic disorders such as diabetes, also hemoglobinopathy and rare pathologies. Following the acquisition of Orgentec, Corgenix and Arotec in 2021, Sebia now develops and markets innovative solutions for autoimmunity diagnostics and infectious diseases. Headquartered in Lisses, France, the company operates across more than 140 countries with 23 direct subsidiaries. www.sebia.com
About Warburg Pincus
Warburg Pincus LLC is the pioneer of global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than USD 86 billion in assets under management, and more than 220 companies in their active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,000 companies across its private equity, real estate, and capital solutions strategies.
The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit https://www.warburgpincus.com or follow us on LinkedIn.
Media contacts
Sebia
Ivana Gautier
Group General Counsel & Compliance Director
igautier@sebia.com
Warburg Pincus
Alice Gibb
Director – Head of Communications, Europe
+44 (0)207 306 30 90
alice.gibb@warburgpincus.com
